An Investigation of Equine Mesenchymal Stem Cell Characteristics from Different Harvest Sites: More Similar Than Not.
Authors: Lombana Karla G, Goodrich Laurie R, Phillips Jennifer Nikki, Kisiday John David, Ruple-Czerniak Audrey, McIlwraith C Wayne
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Bone marrow-derived mesenchymal stem cells (BMDMSCs) have become established in equine orthopaedic practice for treating soft tissue and bone injuries, yet clinicians selecting harvest sites—typically either the sternum or ilium—have lacked comparative data on whether location affects cellular quality. Lombana and colleagues cultured BMDMSCs from 5 ml bone marrow aspirates taken from both sites in five horses, then evaluated their differentiation capacity across multiple lineages, characterised surface marker expression (CD11a/18, CD34, CD44, CD90) via flow cytometry, and assessed gene transduction efficiency using GFP scAAV vectors. Remarkably, no statistically significant differences emerged between sternal and ilial samples across any of the measured parameters, meaning cells from either harvest site demonstrated equivalent multilineage differentiation potential, immunophenotypic profiles, and transduction capacity. This finding simplifies clinical decision-making considerably: practitioners can select their preferred harvest site based on practical considerations—anatomical access, operator experience, or patient-specific factors—without compromising stem cell quality, though individual variation between horses and specific clinical applications warrant ongoing clinical correlation.
Read the full abstract on PubMed
Practical Takeaways
- •Either the sternum or ilium can be used as a bone marrow harvest site for MSC therapy without compromising cell quality or therapeutic potential
- •Choice of harvest site can be made based on clinical accessibility, patient comfort, and operator preference rather than cell biology considerations
- •Clinicians need not be concerned about inferior cell characteristics if ilial or sternal approach is selected based on practical factors
Key Findings
- •Mesenchymal stem cells harvested from sternal and ilial bone marrow showed no statistically significant differences in multilineage differentiation capacity
- •Cell surface marker expression (CD11a/18, CD34, CD44, CD90) was equivalent between sternal and ilial MSC sources
- •Gene transduction efficiency using GFP scAAV demonstrated no significant differences between harvest sites